Zura Bio Limited
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zura Bio Limited is a clinical-stage biotechnology firm dedicated to crafting innovative therapeutic solutions for a variety of autoimmune and inflammatory conditions. The company's pipeline features tibulizumab (ZB-106), a leading dual-pathway antibody designed to target both IL-17A and B-cell activating factor, which is currently undergoing two distinct Phase 2 clinical investigations for systemic sclerosis and hidradenitis suppurativa. Additionally, Zura Bio is advancing crebankitug (ZB-168), a monoclonal antibody that inhibits the IL-7 receptor alpha chain, influencing diseases driven by the IL-7 and TSLP immune pathways, having successfully concluded Phase 1/1b studies. Another key asset is torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to mitigate inflammation, which has also completed Phase 1/1b (or Phase 1/2) clinical development and is poised for further progression in autoimmune and inflammatory indications. The corporate office for this enterprise is situated in Henderson, Nevada.
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Moderate Buy” by Analysts
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $11.60
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio to Participate in Upcoming Investor Conferences
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages
Zura Bio (NASDAQ:ZURA) Trading Up 0.3% – What’s Next?
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
Zura Bio Reports Business Updates and Outlook for 2026